Uncategorized

Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting

Alpine Immune Sciences, Inc. announced that the Company presented new preclinical data from a study of povetacicept in a murine experimental autoimmune myasthenia gravis (EAMG) model during the 148th Annual American Neurological Association (ANA) Meeting in Philadelphia, PA.

Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting Read More »

LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

Liminal BioSciences Inc. announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP.

LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR Read More »

Scroll to Top